| 15.58 0.08 (0.52%) | 10-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 18.61 | 1-year : | 21.74 |
| Resists | First : | 15.93 | Second : | 18.61 |
| Pivot price | 14.46  |
|||
| Supports | First : | 13.71 | Second : | 12.34 |
| MAs | MA(5) : | 15.48 |
MA(20) : | 14.24 |
| MA(100) : | 11.95 |
MA(250) : | 9.03 |
|
| MACD | MACD : | 0.6 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 85.5  |
D(3) : | 89 |
| RSI | RSI(14): 64.6 |
|||
| 52-week | High : | 15.93 | Low : | 4.26 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ADPT ] has closed below upper band by 19.9%. Bollinger Bands are 81.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 15.8 - 15.86 | 15.86 - 15.91 |
| Low: | 15.05 - 15.13 | 15.13 - 15.19 |
| Close: | 15.47 - 15.58 | 15.58 - 15.67 |
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Tue, 14 Oct 2025
Why Adaptive Biotechnologies (ADPT) Is Up 7.1% After Surge in Analyst Optimism on clonoSEQ Progress - simplywall.st
Mon, 13 Oct 2025
JP Morgan Maintains Adaptive Biotechnologies (ADPT) Overweight Recommendation - Nasdaq
Mon, 13 Oct 2025
JP Morgan Raises Price Target for Adaptive Biotechnologies (ADPT) to $17.00 | ADPT Stock News - GuruFocus
Mon, 13 Oct 2025
Tesla To $300? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
Mon, 06 Oct 2025
Adaptive Biotechnologies: Current Moat Is Strong, But Value Rides On Long-Term Innovation (Rating Upgrade) - Seeking Alpha
Wed, 24 Sep 2025
Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt? - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 152 (M) |
| Shares Float | 117 (M) |
| Held by Insiders | 2.3 (%) |
| Held by Institutions | 97.8 (%) |
| Shares Short | 9,590 (K) |
| Shares Short P.Month | 8,430 (K) |
| EPS | -0.82 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.17 |
| Profit Margin | -59.1 % |
| Operating Margin | -42.6 % |
| Return on Assets (ttm) | -14 % |
| Return on Equity (ttm) | -57.6 % |
| Qtrly Rev. Growth | 36.2 % |
| Gross Profit (p.s.) | 0.82 |
| Sales Per Share | 1.34 |
| EBITDA (p.s.) | -0.68 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -80 (M) |
| Levered Free Cash Flow | -19 (M) |
| PE Ratio | -19.24 |
| PEG Ratio | 0 |
| Price to Book value | 13.2 |
| Price to Sales | 11.56 |
| Price to Cash Flow | -29.49 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|